Dlouhodobý efekt erlotinibu u pacienta s nemalobuněčným karcinomem plic ve 3. linii protinádorové léčby - kazuistika
| Title in English | Long-Term Effect of Erlotinib Therapy in the Third Line of Anticancer Treatment in Patient with Non-Small-Cell Lung Cancer - a Case Report |
|---|---|
| Authors | |
| Year of publication | 2020 |
| Type | Article in Periodical |
| Magazine / Source | Klinická onkologie |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.linkos.cz/files/klinicka-onkologie/471/5733.pdf |
| Doi | http://dx.doi.org/10.14735/amko2020226 |
| Keywords | adenocarcinoma of lung; targeted therapy; erlotinib; gefitinib; tyrosine kinase inhibitors |
| Description | Malignant tumorurs of the trachea, the lungs, and the bronchus are the second most common type tumour in the Czech Republic. Approximately three-quarters of cases are diagnosed in an advanced stage (IIIB-IV) and are of the most common causes of death in all cancer groups. Targeted therapy brings a certain level of the improvement of prognostic outlook. In the Czech Republik, 1st and 2nd generation of tyrosine kinase inhibitors (gefitinib, erlotinib, afatinib) are indicated in the first-line anticancer treatment i non small-cell lung cancer in locally advenced and metastatic stage, with proved activating mutation status of the epidermal growth factor receptor. Erlotinib is also indicated for use in the second ar third line of anticancer treatment after a documented failure of previous chemotherapy. |